bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M

bioAffinity Technologies, Inc.

2026-Q1 EPS reported -$0.81 revenue$1,351,527

CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.
Total revenue $1.4M, down 27% from $1.9M due to discontinuing unprofitable pathology services.
Net loss $3.6M ($0.81/share) vs $2.7M ($4.80/share) in Q1 2025; cash $3.1M.
Physician offices ordering CyPath Lung increased 69% YoY; company expects acceleration.
Launched DoD-funded longitudinal trial; Brooke Army Medical Center study for asthma/COPD companion tests.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

bioAffinity Technologies, Inc. reported first quarter ended March 31, 2026 results: revenue $1.4 million.

Period: first quarter ended March 31, 2026
Revenue: $1.4 million
Result: reported results

Exact text from the filing

Lung testing revenue increased approximately 114% to $361,000 , compared to $169,000 in the first quarter of 2025. ● Total consolidated revenue decreased approximately 27% to $1.4 million , compared to $1.9 million for the first quarter of 2025, resulting from the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin

View on SEC.gov

Browse all earnings releases →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.